Visual pathways involved in fear conditioning measured with fear-potentiated startle: behavioral and anatomic studies.
Visual pathways to the amygdala, a brain structure critical for classical fear conditioning, were investigated. Conditioned fear was measured in rats as increased acoustic startle amplitude in the presence versus absence of a light or an odor paired previously with foot shock (fear-potentiated startle). Post-training lesions of both the lateral geniculate body (LG) and lateral posterior nucleus (LP) of the thalamus together, but not lesions of LG or LP alone, completely blocked the expression of fear-potentiated startle to a visual conditioned stimulus (CS) but not to an olfactory CS. These lesions also did not block contextual fear conditioning using startle or freezing as measures. Local infusion of 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f] quinoxaline-7-sulfonamide disodium, an AMPA antagonist, into the visual thalamus immediately before testing also blocked fear-potentiated startle to a visual CS, suggesting that the lesion effects were not attributable to damage of fibers of passage. Iontophoretic injections into the LP of the anterograde tracer biotinylated dextran amine resulted in heavy anterograde labeling in two amygdala-fugal cortical areas: area TE2 and dorsal perirhinal cortex (PR), and moderate labeling in the lateral amygdaloid nucleus (L). These results suggest that, during classical fear conditioning, a visual stimulus can be transmitted to the amygdala via either lemniscal (i.e., LG --> V1, V2 --> TE2/PR) or non-lemniscal (i.e., LP --> V2, TE2/PR) thalamo-cortico-amygdala pathways, or direct thalamo-amygdala (i.e., LP --> L) projections.
Shi
C
C
Department of Psychiatry and Behavior Science and Center for Behavior Neuroscience, Emory University School of Medicine, Atlanta, Georgia 30322, USA. cshi@emory.edu
Davis
M
M
D000679:Amygdala / Q000033:anatomy & histology / Q000502:physiology*; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D001710:Biotin / Q000031:analogs & derivatives*; D003214:Conditioning, Classical; D003911:Dextrans; D004597:Electroshock; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005239:Fear / Q000502:physiology*; D008297:Male; D009812:Odorants; D010775:Photic Stimulation; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D013216:Reflex, Startle / Q000502:physiology*; D012903:Smell / Q000502:physiology; D013268:Stimulation, Chemical; D013787:Thalamic Nuclei / Q000187:drug effects / Q000502:physiology; D013788:Thalamus / Q000187:drug effects / Q000502:physiology; D014795:Visual Pathways / Q000033:anatomy & histology / Q000502:physiology*
D003911:Dextrans; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; C076397:biotinylated dextran amine; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D001710:Biotin